



Bee Vectoring Technologies Receives Key Patent Allowances in Canada, Russia and Australia

MISSISSAUGA, ON – APRIL 28, 2016 – Bee Vectoring Technologies International Inc. (the “Company” or “BVT”) (TSXV: BEE) announces the allowance of the following patent applications:

- Canadian Patent application No. 2832518, and Russian Patent Application No. 2013149575, both entitled “Bee Vectoring Apparatus”, being the BVT Dispenser System noted in (1) below.
- Australian Patent Application No. 2013232699, entitled “A Formulation Comprising A Particulate Calcium Silicate and *Clonostachys Rosea* For Treating Plants”, being Vectorite noted in (2) below.

These patent applications are part of a portfolio of over 40 applications worldwide that cover various aspects of BVT’s key technologies. BVT describes its key technologies as including (1) the BVT Dispenser System; (2) the Vectorite™ brand composition; and (3) the active ingredient CR-7:

(1) The BVT Dispenser System is an apparatus for the treatment of plants that includes an inoculum dispenser and a tray. The BVT inoculum dispenser system is incorporated into the lid of commercial bumblebee hives. In the dispenser is a removable tray that contains, in powder form, the inoculant crop control and a mixture of products (Vectorite™ brand composition) that allows the bees to effectively pick up the product on their way out of the hive.

(2) Vectorite™ brand composition is a proprietary mixture of products that allows the inoculant to attach to a bee’s hairy legs and body as it walks through the tray on its way out of the hive. Vectorite™ brand composition allows for delivery of BVT inoculums, either individually, or together with other bio-controls and crop controls.

(3) CR-7 is a specific strain of Fungi from the genus *Clonostachys Rosea* which is known to be an endophyte and blocks pathogens from rapid colonization of plants. The mode of action of the Fungi, which is one of a pioneer coloniser and occupier, is to stimulate growth and block diseases such as Botrytis and Sclerotinia. When used as a foundational program in high value crops it is effective in controlling key diseases that can cause enormous commercial losses in crops.

BVT CEO, Michael Collinson said *“These latest patent application allowances not only further strengthen BVT’s IP portfolio, but come in key territories where we believe there are considerable revenue-generating opportunities. We continue to clearly execute on our established business plan and keenly pursue a significant number of revenue-generating business opportunities across several global territories.”*

About [Bee Vectoring Technologies International Inc.](#)

BVT has developed and owns patent-pending bee vectoring technology (consisting of a proprietary tray dispenser containing a unique carrier agent) that is designed to harmlessly

utilize commercially reared bumblebees as natural delivery mechanisms for a variety of powdered mixtures comprised of organic compounds that inhibit or eliminate common crop diseases, while at the same time stimulating and enhancing the same crops. This unique and proprietary process facilitates a targeted delivery of crop controls using the simple process of bee pollination to replace traditional crop spraying, resulting in better yield, organic product and less impact on the environment without the use of water or disruptions to labour.

Additional information can be viewed at the Company's website www.beevt.com.

On Behalf of the Board of Directors of Bee Vectoring Technologies International Inc.

"Michael Collinson"
President & CEO

For further information, please contact:

Michael Collinson, President & CEO

Tel: 647-660-5119

marketing@beevt.com

For media enquiries or interviews, please contact:

Josh Stanbury | josh@sjspr.co.uk | T. 416-628-7441

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release contains certain "forward-looking statements" that involve known and unknown risks and uncertainties. All statements in this press release, other than statements of historical fact, that address events or developments that BVT expects to occur, are forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements with respect to BVT'S future plans and technologies, including the timing of such plans and technologies. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential", "indicate" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although BVT believes that the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include continued availability of capital, financing and required resources (such as human resources, equipment and/or other capital resources), and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of BVT'S management on the date the statements are made. BVT undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change, except as required by law.